EP Patent
EP2176231B1 — Substituted indazole derivatives active as kinase inhibitors
Assigned to Nerviano Medical Sciences SRL · Expires 2016-10-19 · 10y expired
What this patent protects
Patent listed against Rozlytrek.
Drugs covered by this patent
- Rozlytrek (entrectinib) · Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.